Human cardiac organoids have revolutionized the study of cardiac development,disease modeling,drug discovery,and regenerative therapies.This review systematically discusses strategies and progress in the construction ...Human cardiac organoids have revolutionized the study of cardiac development,disease modeling,drug discovery,and regenerative therapies.This review systematically discusses strategies and progress in the construction of cardiac organoids,categorizing them into three main types:cardiac spheroids,self-organizing/assembloid organoids,and organoid-on-a-chip systems.This review uniquely integrates the advances in vascularization,organ-on-chip design,and environmental cardiotoxicity modeling within cardiac organoid platforms,offering a critical synthesis that is absent in the literature.In the context of escalating environmental threats to cardiovascular health,there is an urgent need for physiologically relevant models to accurately identify cardiac toxicants and elucidate their underlying mechanisms of action.This review highlights advances in cardiac organoid applications for disease modeling—including congenital heart defects and acquired cardiovascular diseases—drug development,toxicity screening,and the study of environmentally induced cardiovascular pathogenesis.In addition,it critically examines ongoing challenges and underscores opportunities brought by bioengineering approaches.Finally,we propose future directions for developing standardized cardiac organoid platforms with clinical predictability,aiming to expand the utility of this technology across broader research applications.展开更多
基金supported by the Innovation Promotion Program of NHC and Shanghai Key Labs,SIBPT(grant number PT2025-01)。
文摘Human cardiac organoids have revolutionized the study of cardiac development,disease modeling,drug discovery,and regenerative therapies.This review systematically discusses strategies and progress in the construction of cardiac organoids,categorizing them into three main types:cardiac spheroids,self-organizing/assembloid organoids,and organoid-on-a-chip systems.This review uniquely integrates the advances in vascularization,organ-on-chip design,and environmental cardiotoxicity modeling within cardiac organoid platforms,offering a critical synthesis that is absent in the literature.In the context of escalating environmental threats to cardiovascular health,there is an urgent need for physiologically relevant models to accurately identify cardiac toxicants and elucidate their underlying mechanisms of action.This review highlights advances in cardiac organoid applications for disease modeling—including congenital heart defects and acquired cardiovascular diseases—drug development,toxicity screening,and the study of environmentally induced cardiovascular pathogenesis.In addition,it critically examines ongoing challenges and underscores opportunities brought by bioengineering approaches.Finally,we propose future directions for developing standardized cardiac organoid platforms with clinical predictability,aiming to expand the utility of this technology across broader research applications.
